Abstract
Purpose Segmentation of involved lymph nodes on head and neck computed tomography (HN-CT) scans is necessary for the radiotherapy treatment planning of human papilloma virus (HPV) associated oropharynx cancers (OPC). We aimed to train a deep learning convolutional neural network (DL-CNN) to identify and segment involved lymph nodes on contrast-enhanced HN-CT scans.
Methods 90 patients who underwent levels II-IV neck dissection for newly diagnosed, clinically node-positive, HPV-OPC were identified. Ground-truth segmentation of all radiographically and pathologically involved nodes was manually performed on pre-surgical HN-CT scans, which were randomly divided into training/validation dataset (n=70) and testing dataset (n=20). A 5-fold cross validation was used to train 5 separate DL-CNN sub-models based on a residual U-net architecture. Validation and testing segmentation masks were compared to ground-truth segmentation masks using overlap-based, volume-based, and distance-based metrics. A lymph auto-detection model was developed by thresholding segmentation model outputs, and 20 node-negative HN-CT scans were added to the test set to further evaluate auto-detection capabilities. Model discrimination of lymph node “positive” and “negative” HN-CT scans was evaluated using the area under the receiver operating characteristic curve (AUC).
Results In the DL-CNN validation phase, all sub-models yielded segmentation masks with median DSC ≥ 0.90 and median volume similarity score of ≥ 0.95. In the testing phase, the DL-CNN produced consensus segmentation masks with median Dice of 0.92 (IQR, 0.89-0.95), median volume similarity of 0.97 (IQR, 0.94-0.99), and median Hausdorff distance of 4.52 mm (IQR, 1.22-8.38). The detection model achieved an AUC of 0.98.
Conclusion The results from this single-institution study demonstrate the successful automation of lymph node segmentation for patients with HPV-OPC using a DL-CNN. Future studies, including external validation using a larger dataset, are necessary to clarify the role of the DL-CNN in the routine radiation oncology treatment planning workflow.
Competing Interest Statement
C.D.F. has received direct industry grant support, speaking honoraria, and travel funding from Elekta AB. The other authors have no conflicts of interest to disclose.
Funding Statement
This work was supported by the National Institutes of Health (NIH)/National Cancer Institute (NCI) through a Cancer Center Support Grant (CCSG; P30CA016672-44). M.A.N. is supported by an NIH grant (R01DE028290-01). K.A.W. is supported by a training fellowship from The University of Texas Health Science Center at Houston Center for Clinical and Translational Sciences TL1 Program (TL1TR003169), the American Legion Auxiliary Fellowship in Cancer Research, and an NIH/National Institute for Dental and Craniofacial Research (NIDCR) F31 fellowship (1 F31DE031502-01). C.D.F. received funding from the NIH/NIDCR (1R01DE025248-01/R56DE025248); an NIH/NIDCR Academic-Industrial Partnership Award (R01DE028290); the National Science Foundation (NSF), Division of Mathematical Sciences, Joint NIH/NSF Initiative on Quantitative Approaches to Biomedical Big Data (QuBBD) Grant (NSF 1557679); the NIH Big Data to Knowledge (BD2K) Program of the NCI Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science Award (1R01CA214825); the NCI Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program (1R01CA218148); an NIH/NCI Pilot Research Program Award from the UT MD Anderson CCSG Radiation Oncology and Cancer Imaging Program (P30CA016672); an NIH/NCI Head and Neck Specialized Programs of Research Excellence (SPORE) Developmental Research Program Award (P50CA097007); and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) Research Education Program (R25EB025787).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of The University of Texas MD Anderson Cancer Center gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
